Kaleido Biosciences Announces Closing of Initial Public Offering

LEXINGTON, Mass., March 04, 2019 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to leveraging the potential of the microbiome organ to treat disease and improve human health, today announced the closing of its initial public offering of 5,000,000 shares of common stock at a public offering price of $15.00 per share. The gross proceeds from the offering were $75 million before deducting underwriting discounts and commissions and estimated offering expenses. All of the shares in the offering were offered by Kaleido. The shares commenced trading on The Nasdaq Global Select Market on February 28, 2019, under the ticker symbol “KLDO.”

Goldman Sachs, J.P. Morgan and Morgan Stanley acted as joint book-running managers for the offering. Canaccord Genuity acted as lead manager for the offering.

The offering was made only by means of a prospectus. Copies of the final prospectus may be obtained from Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, New York 10282, telephone: 1-866-471-2526, facsimile: 212-902-9316, or email: [email protected]; from J.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, telephone: 1-866- 803-9204, or email: [email protected]; or from Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014.

A registration statement relating to the shares being sold in this offering has been filed with the Securities and Exchange Commission and became effective on February 27, 2019. Copies of the registration statement can be accessed through the SEC’s website at www.sec.gov. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Kaleido BiosciencesKaleido Biosciences is a clinical-stage healthcare company with a differentiated, chemistry-driven approach to leveraging the potential of the microbiome organ to treat disease and improve human health. The Company has built a human-centric proprietary product platform to enable the rapid and cost-efficient discovery and development of novel Microbiome Metabolic Therapies (MMT™). MMTs are designed to modulate the metabolic output and profile of the microbiome by driving the function and distribution of the organ’s existing microbes. Kaleido is advancing a broad pipeline of MMT candidates with the potential to address a variety of diseases and conditions with significant unmet patient needs.

ContactKaleido Biosciences Amy Reilly 617-890-5721 [email protected]

You May Also Be Interested In

• Regenxbio prices $100M public offering of stock and warrants
• Gold Resource set to lose Russell 2000 index eligibility after merger
• IPG Photonics to acquire Lumibird Medical for up to €350M